Nature Communications (Sep 2016)
Identification of KasA as the cellular target of an anti-tubercular scaffold
- Katherine A. Abrahams,
- Chun-wa Chung,
- Sonja Ghidelli-Disse,
- Joaquín Rullas,
- María José Rebollo-López,
- Sudagar S. Gurcha,
- Jonathan A. G. Cox,
- Alfonso Mendoza,
- Elena Jiménez-Navarro,
- María Santos Martínez-Martínez,
- Margarete Neu,
- Anthony Shillings,
- Paul Homes,
- Argyrides Argyrou,
- Ruth Casanueva,
- Nicholas J. Loman,
- Patrick J. Moynihan,
- Joël Lelièvre,
- Carolyn Selenski,
- Matthew Axtman,
- Laurent Kremer,
- Marcus Bantscheff,
- Iñigo Angulo-Barturen,
- Mónica Cacho Izquierdo,
- Nicholas C. Cammack,
- Gerard Drewes,
- Lluis Ballell,
- David Barros,
- Gurdyal S. Besra,
- Robert H. Bates
Affiliations
- Katherine A. Abrahams
- Institute of Microbiology and Infection, School of Biosciences, University of Birmingham, Edgbaston
- Chun-wa Chung
- GlaxoSmithKline
- Sonja Ghidelli-Disse
- Cellzome—a GSK Company
- Joaquín Rullas
- Diseases of the Developing World, GlaxoSmithKline
- María José Rebollo-López
- Diseases of the Developing World, GlaxoSmithKline
- Sudagar S. Gurcha
- Institute of Microbiology and Infection, School of Biosciences, University of Birmingham, Edgbaston
- Jonathan A. G. Cox
- Institute of Microbiology and Infection, School of Biosciences, University of Birmingham, Edgbaston
- Alfonso Mendoza
- Diseases of the Developing World, GlaxoSmithKline
- Elena Jiménez-Navarro
- Diseases of the Developing World, GlaxoSmithKline
- María Santos Martínez-Martínez
- Diseases of the Developing World, GlaxoSmithKline
- Margarete Neu
- GlaxoSmithKline
- Anthony Shillings
- GlaxoSmithKline
- Paul Homes
- GlaxoSmithKline
- Argyrides Argyrou
- GlaxoSmithKline
- Ruth Casanueva
- Diseases of the Developing World, GlaxoSmithKline
- Nicholas J. Loman
- Institute of Microbiology and Infection, School of Biosciences, University of Birmingham, Edgbaston
- Patrick J. Moynihan
- Institute of Microbiology and Infection, School of Biosciences, University of Birmingham, Edgbaston
- Joël Lelièvre
- Diseases of the Developing World, GlaxoSmithKline
- Carolyn Selenski
- GlaxoSmithKline
- Matthew Axtman
- GlaxoSmithKline
- Laurent Kremer
- Centre National de la Recherche Scientifique FRE 3689, Centre d’études d’agents Pathogènes et Biotechnologies pour la Santé, Université de Montpellier
- Marcus Bantscheff
- Cellzome—a GSK Company
- Iñigo Angulo-Barturen
- Diseases of the Developing World, GlaxoSmithKline
- Mónica Cacho Izquierdo
- Diseases of the Developing World, GlaxoSmithKline
- Nicholas C. Cammack
- Diseases of the Developing World, GlaxoSmithKline
- Gerard Drewes
- Cellzome—a GSK Company
- Lluis Ballell
- Diseases of the Developing World, GlaxoSmithKline
- David Barros
- Diseases of the Developing World, GlaxoSmithKline
- Gurdyal S. Besra
- Institute of Microbiology and Infection, School of Biosciences, University of Birmingham, Edgbaston
- Robert H. Bates
- Diseases of the Developing World, GlaxoSmithKline
- DOI
- https://doi.org/10.1038/ncomms12581
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 13
Abstract
Screens for bactericidal compounds have resulted in promising anti-tubercular hits. Here, the authors analyse in detail the target of an indazole sulfonamide (GSK3011724A), and find that it has a different mode of inhibition compared to other Kas inhibitors of fatty acid biosynthesis in bacteria.
